Everand Logo

Welcome to Everand!

  • STAT

    After two years, diabetes patients see gains with startup’s digital coaching — and some drop-off

    New data from Virta Health underscore a tricky challenge for health tech companies: Health gains often erode over time.
    by Rebecca Robbins Jun 05, 2019 3 minutes
    Source: Mary Altaffer/AP

    A version of this story appeared in STAT Health Tech, our weekly newsletter about how tech is transforming health care and the life sciences. Sign up here to receive it in your inbox.

    SAN FRANCISCO — Plenty of health-tech startups have been buoyed by early data suggesting that their coaching and monitoring tools are generating improvements in patients with chronic diseases.

    But a big question remains: Just how durable are those gains?

    New data from one such company, Virta Health, underscore a tricky challenge for the burgeoning field: Even when

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
    Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
    STAT2 min readAmerican Government
    STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
    The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

    Related Books & Audiobooks